BRIEF—Deal to bring Alzheimer's patch to South Korean market

Luye Pharma Group has entered into an agreement with Myung In Pharm, granting the latter the exclusive rights to commercialize rivastigmine twice weekly transdermal patch in South Korea.

Developed by China-based Luye Pharma, this drug is a first-line treatment for mild to moderate dementia associated with Alzheimer's disease.

It has not yet been granted regulatory approval in South Korea, though has been approved for marketing in multiple European countries and China.

Myung In Pharm is a leader in South Korea in the central nervous system (CNS) therapeutic area. The company has a strong portfolio targeting CNS diseases.